Jasper Therapeutics, Inc. Common Stock earnings per share and revenue
On 10 de nov. de 2025, JSPR reported earnings of -1.25 USD per share (EPS) for Q3 25, missing the estimate of -1.23 USD, resulting in a -0.87% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analistas forecast an EPS of -0.68 USD, with revenue projected to reach -- USD, implying an diminuir of -45.60% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Jasper Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Jasper Therapeutics, Inc. Common Stock reported EPS of -$1.25, missing estimates by -0.87%, and revenue of $0.00, 0% as expectations.
How did the market react to Jasper Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved -- 0%, changed from $1.78 before the earnings release to $1.78 the day after.
When is Jasper Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for Jasper Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analistas, Jasper Therapeutics, Inc. Common Stock is expected to report EPS of -$0.68 and revenue of -- for Q4 2025.